  We used redescription mining to find interpretable rules revealing
associations between those determinants that provide insights about the
Alzheimer's disease (AD). We extended the CLUS-RM redescription mining
algorithm to a constraint-based redescription mining (CBRM) setting, which
enables several modes of targeted exploration of specific, user-constrained
associations. Redescription mining enabled finding specific constructs of
clinical and biological attributes that describe many groups of subjects of
different size, homogeneity and levels of cognitive impairment. We confirmed
some previously known findings. However, in some instances, as with the
attributes: testosterone, the imaging attribute Spatial Pattern of
Abnormalities for Recognition of Early AD, as well as the levels of leptin and
angiopoietin-2 in plasma, we corroborated previously debatable findings or
provided additional information about these variables and their association
with AD pathogenesis. Applying redescription mining on ADNI data resulted with
the discovery of one largely unknown attribute: the Pregnancy-Associated
Protein-A (PAPP-A), which we found highly associated with cognitive impairment
in AD. Statistically significant correlations (p <= 0.01) were found between
PAPP-A and various different clinical tests. The high importance of this
finding lies in the fact that PAPP-A is a metalloproteinase, known to cleave
insulin-like growth factor binding proteins. Since it also shares similar
substrates with A Disintegrin and the Metalloproteinase family of enzymes that
act as {\alpha}-secretase to physiologically cleave amyloid precursor protein
(APP) in the non-amyloidogenic pathway, it could be directly involved in the
metabolism of APP very early during the disease course. Therefore, further
studies should investigate the role of PAPP-A in the development of AD more
thoroughly.
